SciClone Pharmaceuticals' oncology segment is dedicated to the development and commercialization of therapies for various cancer types. This includes targeted therapies and immunotherapies aimed at improving patient outcomes and extending survival. The company actively engages in clinical trials to evaluate the efficacy and safety of novel anticancer agents. Key products in this segment address unmet needs in the treatment of solid tumors and hematological malignancies. SciClone's strategic partnerships and licensing agreements further enhance its oncology portfolio, providing access to innovative treatments for the China market and beyond. The company's focus on precision medicine and personalized approaches aims to deliver tailored therapies that maximize patient benefit and minimize adverse effects.

The infectious diseases segment at SciClone Pharmaceuticals focuses on developing and commercializing treatments for severe and life-threatening infections. This includes both proprietary products like Zadaxin and in-licensed products targeting a range of bacterial and viral infections. The company's R&D efforts are directed towards identifying and developing novel anti-infective agents to combat emerging and drug-resistant pathogens. SciClone's commercial operations in China and other international markets ensure broad access to these critical therapies. The company also collaborates with research institutions and other pharmaceutical companies to advance the development of innovative treatments for infectious diseases, addressing the growing global threat of antimicrobial resistance and improving patient outcomes in this critical therapeutic area.